Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | TERT | O14746 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862959 | 1.00 | NPC1 (0.47) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL12238275 | 0.89 | GRM8 (0.50) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL12267029 | 0.89 | GRM8 (0.50) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL8199417 | 0.89 | GRM8 (0.50) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| Hydrochloric Acid SCHEMBL2327708 | 0.87 | GRM8 (0.49) | NPC1RAB9AALDH1A1MAPK1FOLH1 | |
| SCHEMBL17690014 | 0.87 | HDAC3 (0.49) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL3862343 | 0.87 | SMN1; SMN2 (0.54) | L3MBTL1TERTNAAASMN1; SMN2 | |
| SCHEMBL13884683 | 0.86 | ITGB3 (0.47) | NPC1RAB9AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4889040 | 0.85 | HDAC1 (0.56) | NPC1RAB9AALDH1A1MAPK1POLB | |
| SCHEMBL13884634 | 0.83 | FOLH1 (0.47) | NPC1RAB9AALDH1A1L3MBTL1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100580087-C | Conjugation of peptides | NOVO NORDISK HEALTHCARE AG | 2010-01-13 | — | — | CN | claimed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | claimed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| JP-2008531482-A | — | — | 2008-08-14 | — | — | JP | claimed |
| EP-1850878-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2007-11-07 | — | — | EP | claimed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | claimed |
| CN-1863920-A | Conjugation of peptides | NOVO NORDISK AS (DK) | 2006-11-15 | — | — | CN | claimed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | claimed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | claimed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | claimed |
| CN-100580087-C | Conjugation of peptides | NOVO NORDISK HEALTHCARE AG | 2010-01-13 | — | — | CN | disclosed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1850878-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2007-11-07 | — | — | EP | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| CN-1863920-A | Conjugation of peptides | NOVO NORDISK AS (DK) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | NPC1 2911/4885RAB9A 3608/4885ALDH1A1 3531/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | NPC1 3576/4885RAB9A 3236/4885ALDH1A1 2226/4885 |
| US-20090253166-A1 | Conjugation of Peptides | DNPEP, ENPEP, ANPEP | NPC1 3576/4885RAB9A 3236/4885ALDH1A1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.